CD8A and graft versus host disease: We demonstrated the potential of expanded CD8+CD45RClow/− Tregs as a cellular therapy in two models of human immune responses in NSG humanized mice rejecting either allogeneic human skin graft or developing an acute xenogeneic GVHD.